2022/05/23

Shionogi Announces appointment of Corporate officers, Corporate Reorganization and Personnel Reassignment

OSAKA, Japan, May 23, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.;hereafter "Shionogi") announced that it will implement a reorganization of the Shionogi Group, including changes in responsibilities of candidates for Directors,appointment of Corporate Officers, and mergers of Group companies, as well as personnel reassignments as described below, effective July 1, 2022.

 

1.       Change in responsibilities of candidate for directors (Effective; July 1, 2022)

New (or continuing) Position

Name

Present Position

Chief Executive Officer

Isao Teshirogi

Representative Director, President and CEO

Director and Vice Chairperson of the Board

Takuko Sawada

Director and Executive Vice President

 

2.       Appointment of Corporate Officers (Effective; July 1, 2022)

New Position

Name

Present Position

Senior Executive Officer,

Senior Vice President,

Research Division

Yasuyoshi Isou

Corporate Officer,

Senior Vice President,

CMC R&D Division

Corporate Officer,

Senior Vice President,

DX Promotion Division

Masashi Deguchi

Vice President,

Project Management Department

Corporate Officer,

Senior Vice President,

Biopharmaceutical Research Division

Yasunori Aoyama

Vice President,

Analytical R&D Laboratory

Corporate Officer,

Senior Vice President, Integrated Disease Care Division

Yousuke Miharu

Vice President,

New Product Planning Department

Corporate Officer,

Senior Vice President,

Drug Development and Regulatory Science Division

Takeki Uehara

Vice President,

Clinical Research Department

 

3.       Purpose of corporate reorganization and new establishment

In the medium-term business plan “Shionogi Transformation Strategy 2030 (STS2030),” the Shionogi Group expressed its intention to evolve from a drug-discovery-based pharmaceutical company that mainly provides ethical drugs into a HaaS (Healthcare as a Service) company that provides comprehensive healthcare services. Amid rapid changes in the business environment and in the needs of society, in order to respond flexibly to those changes and more comprehensively solve the issues facing patients and society, we must continue transforming ourselves into an organization with the ability to make prompt and effective decisions and execute efficient business operations. Based on this concept, in order to further clarify the responsibilities for business execution and to strengthen cooperation among related divisions, new supervisory organizations in charge of each major value chain (R&D, healthcare business, supply, and corporate) will be established. We will change the organization as follows, along the aforementioned lines. Organizations that are newly established or reorganized are indicated by "parentheses".

 

I.     The R&D Supervisory Unit will oversee three divisions: “Research Division”, “Biopharmaceutical Research Division”, and Drug Development and Regulatory Science Division.

・   The Pharmaceutical Research Division and the CMC R&D Division will be reorganized into the Research Division and the Biopharmaceutical Research Division to increase the efficiency and speed of the process from drug discovery research to manufacturing method design and to advance the development of drugs with new modalities.

・   The Research Division consists of the Laboratory for Drug Discovery and Disease Research, the Laboratory for Medicinal Chemistry Research, the Laboratory for Drug Discovery and Development, the API R&D Laboratory, the Formulation R&D Laboratory, and the Intellectual Property Department.

・   The Laboratory for Bio-Drug Discovery, the Laboratory for Bio-Modality Research, and the Analysis and Evaluation Laboratory will be newly established under the Biopharmaceutical Research Division.

・   In order to further strengthen collaboration with third parties in drug discovery from the R&D stage, the "Investment Strategy Department" will be newly established to handle strategic investment outside the company, and the Business Development Department under the Corporate Strategy Division will be placed directly under the R&D Supervisory Unit.

・   The R&D functions of the Biomarker R&D Department will be incorporated into the related functions of the Research Division and the Biopharmaceutical Research Division  in order to enhance their respective specialties.

 

II.      The Healthcare Business Supervisory Unit will oversee the Pharmaceutical Commercial Division and the Inteqrated Disease Care Division.

・   The seven Pharmaceutical Promotion Departments under the Pharmaceutical Commercial Division will be reorganized into five Pharmaceutical Promotion Departments.

・   To strengthen the cooperation with the strategy planning/promotion function and sales function related to the HaaS business, the "New Business Promotion Department" will be newly established under the Integrated Disease Care Division.

・   The Regulatory Affairs Department under the Drug Development and Regulatory Science Division will be incorporated into the Healthcare Business Supervisory Unit to enhance coordination between business activities and regulatory affairs activities.

・   To promote efficient business operations from vaccine development to sales, the “Vaccine and Diagnostic Drug Department” will be newly established directly under the Healthcare Business Supervisory Unit by consolidating the Vaccine Business Department of the Inteqrated Disease Care Division and the business functions of the Biomarker R&D Department of the Pharmaceutical Research Division. Under the Vaccine and Diagnostic Drug Department, the “Diagnostic Drug Office” and the “Partnership Promotion Office” will be established.

 

III.    The Supply Supervisory Unit will oversee the Global Business Division, overseas Group companies and production Group companies.

・   In addition to overseas Group companies and the Global Business Division, which comprises the Global Business Department and the Global Supply Chain Strategy Department, the Supply Supervisory Unit will also oversee Group companies involved in production to strengthen cooperation among all relevant companies so as to enable more efficient and flexible production and supply of products on a global basis.

 

IV.    The Corporate Supervisory Unit will oversee the Corporate Strategy Division, the Administration Division, the DX Promotion Division, and the Corporate Quality Assurance and Ethics & Compliance Management Division.

・   Management and indirect functions previously distributed across the company will be consolidated into the Administration Division, and the “Value Chain Support Department” will be newly established. Under this new Department, the “R&D Support Office” and the “Healthcare Business Support Office” will be established to strengthen cooperation between each supervisory unit/division and headquarters.

・   Under the Human Resources Department, the “Human Capital Strategy Office” and the “Career Development Office” will be newly established.

・   The Digital Intelligence Department of the DX Promotion Headquarters will be eliminated and transferred to the relevant organization for each function.

 

 

4.       Merger among Group Companies (Please refer to “Overview of the Merger” below.)

An absorption-type merger will be executed among Shionogi’s Group companies, in which Shionogi Business Partner Co., Ltd., a wholly-owned subsidiary of Shionogi, will be the surviving company and Shionogi Administration Service Co., Ltd., Shionogi Career Development Center Co., Ltd., and Shionogi Marketing Solutions Co., Ltd. will be the absorbed companies. This merger is intended to consolidate the indirect functions of these companies and eliminate duplicative functions such as management and administration, thereby creating an efficient organization that can flexibly handle fluctuations between busy and slow periods by classifying operations into two categories (those that require highly specialized expertise and abundant experience and those that do not) and establishing a system that allows flexible movement of personnel, such that, if a business is short of staff during a busy period, workers can be borrowed from other businesses.

 

 

5.       Personnel Reassignments (Effective; July 1, 2022)

New (or continuing) Position

Name

Present Position

R&D Supervisory Unit

Senior Executive Officer,

Senior Vice President,

R&D Supervisory Unit

John Keller

Senior Executive Officer,

Senior Vice President,

Corporate Strategy Division

Vice President, Business Development Department

Yuki Tachibana

Laboratory for Medicinal Chemistry Research

Vice President,

Investment Strategy Department

Takeaki Dohda

DX Promotion Division

Research Division

Senior Executive Officer,

Senior Vice President,

Research Division

Yasuyoshi Isou

Corporate Officer,

Senior Vice President,

CMC R&D Division

Vice President,

Laboratory for Drug Discovery and Disease Research

Takafumi Sato

Pharmaceutical Research Division

Vice President,

API R&D Laboratory

Takayuki Tsuritani

API R&D Laboratory

President,

Shionogi Techno Advance Research Co., Ltd.

Toshiyuki Asaki

President,

Shionogi Career Development Center Co., Ltd.

Biopharmaceutical Research Division

Corporate Officer,

Senior Vice President,

Biopharmaceutical Research Division

Yasunori Aoyama

Vice President,

Analytical R&D Laboratory

Vice President,

Laboratory for Bio-Drug Discovery

Mina Yamamoto

Vice President,

Laboratory for Innovative Therapy Research

Vice President,

Laboratory for Bio-Modality Research

Akira Ino

Vice President,

API R&D Laboratory

Vice President,

Analysis and Evaluation Laboratory

Izumi Ishikawa

Shionogi Career Development Center Co., Ltd.

Drug Development and Regulatory Science Division

Corporate Officer,

Senior Vice President,

Drug Development and Regulatory Science Division

Takeki Uehara

Vice President,

Clinical Research Department

Vice President,

Project Management Department

Shouko Kan-o

Vice President,

Research Planning Department

Vice President,

Clinical Research Department

Natsuko Oda

Clinical Research Department

Healthcare Business Supervisory Unit

Senior Executive Officer,

Senior Vice President,

Healthcare Business Supervisory Unit and Pharmaceutical Commercial Division

Toshinobu Iwasaki

Senior Executive Officer,

Senior Vice President,

Drug Development and Regulatory Science Division

Vice President,

Vaccine and Diagnostic Drug Department

Norio Tamura

Vice President,

Vaccine Business Department

Senior Director,

Vaccine and Diagnostic Drug Department,

Diagnostic Drug Office

Tomoyuki Yukizawa

Vice President,

Biomarker R&D Department

Senior Director,

Vaccine and Diagnostic Drug Department,

Partnership Promotion Office

Mikiya Takeuchi

Vice President,

Business Development Department

Vice President,

Tokyo Branch Office

Junichiro Akiyoshi

Tokyo Branch Office

Pharmaceutical Commercial Division

Vice President,

Pharmaceutical Commercial Division

Yoshinori Yurugi

Senior Director, Pharmaceutical Promotion Department - Region 3

Senior Director,

Promotion Department - Region 1

Harumi Shimazui

Shionogi Pharma Co., Ltd

Senior Director,

Promotion Department - Region 2

Toshiyuki Aoi

Senior Director,

Specialty Product Office

Senior Director,

Promotion Department - Region 3

Masashi Katsumata

Senior Director, Pharmaceutical Promotion Department - Region 4

Senior Director,

Promotion Department - Region 4

Kazuya Ishida

Senior Director, Pharmaceutical Promotion Department - Region 5

Senior Director,

Promotion Department - Region 5

Souichirou Mitsutake

Senior Director, Pharmaceutical Promotion Department - Region 7

Senior Director,

Specialty Product Office

Masao Morishita

Senior Director, Pharmaceutical Promotion Department - Region 6

Integrated Disease Care Division

Corporate Officer,

Senior Vice President, Integrated Disease Care Division

Yousuke Miharu

Vice President,

New Product Planning Department

Vice President,

New Product Planning Department

Michitaka Shichijo

Corporate Planning Department

Vice President,

Corporate Social Responsibility Department and President, Shionogi Smile Heart Co., Ltd.

Hiroyuki Tanaka

Vice President,

Corporate Social Responsibility Department  and Office for Children’s Bright Future

Senior Director,

Corporate Social Responsibility Department, Office for Children’s Bright Future

Kumiko Masuda

Project Management Department

Vice President,

New Business Promotion Department

Hiroyuki Kobayashi

Vice President,

Digital Intelligence Department

Supply Supervisory Unit

Senior Executive Officer,
Senior Vice President,

Supply Supervisory Unit and Global Business Division

Koji Hanasaki

Senior Executive Officer, Senior Vice President,

Global Business Division

Chairman,

Shionogi Pharma Co., Ltd

Ryuichi Kume

President,

Shionogi Pharma Co., Ltd

Corporate Officer,

President,

Shionogi Pharma Co., Ltd

Akira Kato

Corporate Officer,

President, Shionogi Inc.

Vice President,

Shionogi Pharma Co., Ltd

Jun-ichi Hirai

Vice President,

Corporate Quality  Assurance Supervisor

Global Business Division

President,

Shionogi Inc.

Nathan McCutcheon

Shionogi Inc.

Corporate Supervisory Unit

Senior Executive Officer,  Senior Vice President, Corporate Supervisory Unit

Noriyuki Kishida

Senior Executive Officer, Senior Vice President, Administration Division and Legal Affairs Department

Corporate Strategy Division

Senior Executive Officer,

Senior Vice President, Corporate Strategy Division and Corporate Planning Department

Ryuichi Kiyama

Senior Executive Officer, Senior Vice President, Pharmaceutical Research Division

Vice President,

Finance & Accounting Department

Susumu Mitsumori

Vice President,

Corporate Planning Department

Administration Division

Senior Executive Officer,

Senior Vice President, Administration Division

Kazuhiro Hatanaka

Senior Executive Officer, Senior Vice President, Pharmaceutical Commercial Division

Vice President,

Human Resources Department and Value Chain Support Department

Hirofumi Nagatome

Vice President,

Human Resources Department

Vice President,

Legal Affairs Department

Aki Ikebata

Legal Affairs Department

Senior Director,

Human Resources Department,

Human Capital Strategy Office

Takaho Kawamoto

Human Resources Department

Senior Director,

Human Resources Department,

Career Development Office

Yohei Seki

Clinical Research Department

Senior Director,

Value Chain Support Department,

R&D Support Office

Takeshi Sakai

Senior Director,

CMC Planning Office

Senior Director,

Value Chain Support Department,

Healthcare Business Support Office

Wataru Imamura

Senior Director,

Sales Planning Office

President,

Shionogi Business Partner Co., Ltd.

Yuji Hosogai

Vice President,

Finance & Accounting Department

DX Promotion Division

Corporate Officer,

Senior Vice President,

DX Promotion Division

Masashi Deguchi

Vice President,

Project Management Department

Corporate Quality Assurance and Ethics & Compliance Management Division

Corporate Officer,

Senior Vice President, Corporate Quality Assurance and Ethics & Compliance Management Division

Takeshi Shiota

Corporate Officer,

Senior Vice President,

DX Promotion Division

Vice President, Corporate Quality Assurance and Ethics & Compliance Management Division

Toshio Kawakita

Shionogi Pharma Co., Ltd

 

For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html

 

 

References

Summary of merger

1.      Outline of merging companies

Company surviving the Merger

Shionogi Business Partner Company Limited (as of May 23, 2022)

Corporate Name

Shionogi Business Partner Company Limited [SBP]

Location

7-6, Doshomachi 4-chome, Chuo-ku, Osaka

Representative Person

Shigeki Fujita

The main business

Finance and accounting, procurement, purchase, design and copies

Initial Capitalization

10 million yen

Date of Establishment

April 3, 2017

Number of Staff

70 (as of March 31, 2022)

 

 Company absorbed in the Merger

Shionogi Administration Service Company Limited (as of May 23, 2022)

Corporate Name

Shionogi Administration Service Company Limited [SAS]

Location

7-6, Doshomachi 4-chome, Chuo-ku, Osaka

Representative Person

Masao Kashiyama

The main business

Business support for the group companies such as human resources, general administration and internal communications

Initial Capitalization

10 million yen

Date of Establishment

November 2, 1992

Number of Staff

180 (as of March 31, 2022)

 

Shionogi Career Development Center Company Limited (as of May 23, 2022)

Corporate Name

Shionogi Career Development Center Company Limited [SCD]

Location

829-1 Tonouchi, Amagasaki, Hyogo

Representative Person

Toshiyuki Asaki

The main business

1.Career development and support, planning and pursuing career development programs for the Group companies

2.Planning, operation and evaluation of training and development

3.Planning and operation of professional education for each division of Shionogi such as education for new or current sales representatives, globally-focused education

Initial Capitalization

10 million yen

Date of Establishment

April 3, 2017

Number of Staff

26 (as of March 31, 2022)

 

Shionogi Marketing Solutions Company Limited (as of May 23, 2022)

Corporate Name

Shionogi Marketing Solutions Company Limited [SMS]

Location

3-13, Imabashi 3-chome, Chuo-ku, Osaka

Representative Person

Minoru Mitsuda

The main business

1.1Commercial data analysis, sales data management and market research

2.Communication design and creation and management of commercial tools

3.Supporting events such as academic lectures

Initial Capitalization

10 million yen

Date of Establishment

April 3, 2017

Number of Staff

71 (as of March 31, 2022)

 

2.      Status after the merger

Corporate Name

Shionogi Business Partner Company Limited [SBP]

Location

7-6, Doshomachi 4-chome, Chuo-ku, Osaka

Representative Person

Yuji Hosogai